were British Caucasians, and there were no obvious differences in the demography of cases and controls in terms of place of residence within the United Kingdom. Germline DNA from CLL patients was obtained from mouthwashes by using QIAamp DNA mini columns (Qiagen, Crawley, UK) and by following the manufacturer's protocol and quantified using PicoGreen (Invitrogen, Paisley, UK). The study was carried out with informed consent and ethical review board approval in accordance with the tenets of the Declaration of Helsinki Principles.
Genotyping was performed by Kaspar (http://www.kbioscience. co.uk/chemistry/kaspar_chemistry-intro.htm), an allele specific PCR methodology implemented on an ABI7900HT platform (Applied Biosystems, Foster City, CA, USA). We confirmed 96 genotyping results at this single nucleotide polymorphism (SNP) by direct sequencing of 192 samples and obtained perfect concordance, thereby excluding technical artifact influencing findings. PCR primer sequences and amplification conditions are available upon request.
Genotypic frequencies in controls were tested for departure from Hardy-Weinberg equilibrium (HWE) using a w 2 test. The difference between allelic frequencies in cases and controls was calculated using the w 2 test. The risks associated with each SNP were estimated by odds ratios (ORs) using unconditional logistic regression, and associated 95% confidence intervals (CIs) calculated. All computations were undertaken using the statistical software package STATA (Version 8.2, Stata Corporation). A P-value of o0.05 was considered statistically significant in all analyses.
Genotypes for this SNP were successfully generated for all cases. The observed genotype frequencies were in accordance with HWE, providing no evidence of population stratification within the data set. Based on the number of cases and controls analyzed, and the population frequencies of alleles, our study has 80% power to demonstrate an OR of 1.2 associated with rs6983267 stipulating a P-value of 0.05.
Genotype frequencies of rs6983267 were not significantly different between cases (GG, n ¼ 263 (26.7%); GT ¼ 490 (49.8%); TT ¼ 231 (23.5%)) and controls (GG ¼ 1303 (27.0%); GT ¼ 2406 (49.8%); TT ¼ 1122 (23.2%)). There was therefore no evidence for an association between rs6983267 genotype and CLL; P ¼ 0.84 (allelic test) with ORs of 1.01 (95% CI: 0.86-1.19) and 1.02 (95% CI: 0.84-1.23) for heterozygotes and TT homozygotes, respectively. Adjustment for age and sex did not have an impact on study findings (data not shown).
On the basis of our data, there seems little evidence to support the tenet that variation at 8q24 significantly contributes to an inherited genetic susceptibility to CLL. While the underlying basis of an association of 8q24 variation and cancer risk is at present undefined, our data and the recent observation that variation at 8q24 is not associated with breast cancer risk 8 imply that spectrum of tumor risk conferred by this locus may be restricted to certain histologies. A specific feature of APL is its remarkably high incidence observed among populations of Latin origin. Observational studies have found a higher percentage of APL cases among Hispanics in Los Angeles, 3 in the Mexican Mestizo population, 4 in Peru, 5 in Costa Rica, 6 in Spain, 7 in Nicaragua, 8 in Cuba, 9 in Italy, 10 and northwest Iran. 11 However, a recent study found that Hispanics did not have greater lifetime APL incidence rates than Caucasians but that the age distribution among Hispanics was significantly different from non-Hispanic Caucasians, with greater incidence rates for children (1-19 years old) and for adults up to 44 years of age. 12 It has been hypothesized that the overrepresentation of APL among Hispanics could be due to an increase in the single isoform bcr1 (one of the three sites in which PML break points can occur), rather than an equal increase in all three bcr isoforms. 13 There are few reports providing APL incidence rates. Initially, the incidence of APL was estimated by using information from clinical trials of AML, yielding the prediction of 1000 new cases of APL per year in the United States. 12 However, information derived from clinical trials is problematic because of differences in the eligibility, such as age limitation or restriction to de novo AML. A more reliable way of obtaining information on incidence is to use population-based data from cancer registries. Douer 12 used the Cancer Surveillance Program of the Los Angeles County to estimate age-adjusted incidence rates of 1.7 per 1 million males and 1.5 per 1 million females in the period 1980-1995. More information obtained using large populationbased data sets from geographically diverse cancer registries are needed to understand if some ethnicities are truly more prone to chromosomal breakage at a site involved in the t(15;17) translocation and, possibly, to identify potential genetic or environmental risk factors for APL. 12 We have estimated the incidence rates of APL in children below 15 years of age resident in Piedmont (northwest Italy) using data from the Childhood Cancer Registry of Piedmont (CCRP). This is a specialized population-based registry that has been recording cases of malignant tumors in children since 1967. Procedures for data collection, follow-up, tumor classification and inclusion criteria have been reported elsewhere. 14 The CCRP collects both demographic data (gender, town, date of birth and town of residence at diagnosis) and clinical data (date and basis of diagnosis, cancer site and morphology, tumor type, center where diagnosis was made and therapy implemented). Cancer site, morphology and behavior are coded according to the International Classification of Diseases for Oncology (ICD-O-2). Because of its peculiar morphology and uniform association of FAB morphological criteria with the specific chromosomal translocation t(15;17), APL can be coded very reliably even using morphology alone. 12 In the CCRP, reliable data on morphologically diagnosed APL are available from 1980. Morphological and cytogenetic data of cases enrolled in the GIMEMA-AIEOP AIDA protocol have been made available by the Pediatric Oncohematology Clinic of the University of Padua, Italy, where all these analyses have been centralized since 1993. Table 1 . The percentage of APL cases is high and closer to the 23-59% of the reported Central and South American series than to the low German and United States series (3.8-8.7%).
2-12 Agespecific incidence rates are shown in Table 2 : APL rates are fairly constant in the four age groups, whereas those of the other AML subtypes considered together are higher in the first year of life. Ageadjusted incidence rates (standardized on the 1981 census Italian population) were 1.4 (95% confidence interval (CI): 0.6-2.2) and 2.5 (95% CI: 1.2-3.9) per million child-years in 1980-1992 and 1993-2003, respectively; and 1.8 (95% CI: 1.1-2.5) overall . APL incidence rate is higher in the second period, although the difference is not statistically significant.
Of the 14 APL cases diagnosed since 1993, cytogenetic information was available for 12 cases (86%). Translocation t(15;17) was found in 10 cases, subdivided into isoform bcr1 (PML break point in intron 6: three cases), bcr2 (PML break point in exon 6: two cases), and bcr3 (PML break point in intron 3: one case). For four cases, there was no information on the isoforms. Two cases diagnosed with the distinct M3v variant of APL did not have translocation t(15;17). Two cases with no cytogenetic information died within 2 days from clinical diagnosis.
This study is the first population-based report on APL incidence in children (0-14 years old) of Latin origin in Southern Europe. Using CCRP data, we have found high incidence rates of APL among children in a northwestern Italian Abbreviations: AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; FAB, French-American-British; N, number of cases; nos, not otherwise specified. Distribution of AML cases in children (0-14 years) by FAB subtypes (M0-M7). 16 We believe that our data, together with data from geographically and ethnically heterogeneous cancer registries, are helpful to clarify the role of genetic predisposition in the observed ethnic differences of APL incidence rates.
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Real-time PCR was performed with the ABI Prism 7000 Sequence Detector (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions as described previously. 
